FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington	D (	20549	

ck this box if no longer subject to	STATEMENT OF	- CHANGES II	N BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours por rosponso:	0.5						

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
)	obligations may continue. See
	Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Name Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol ATOSSA THERAPEUTICS, INC. [ ATOS ]						Relationship of Reporting Person(s) to Issuer (Check all applicable)							
QUAY STEVEN C					ATOSSIT THEIR LOTTES, INC. [ATOS]						X	Director			10% Ow	ner		
(Last)	(E	First)	(Middle)	_									X	Officer (g below)	jive title		Other (sp	pecify
` ′	`	RAPEUTICS, IN	` '		3. Date of Earliest Transaction (Month/Day/Year)						President & CEO							
	ING STRE		·C.	- [	02/24/2022													
107 51 10	ING STREE	L1																
(Street)				.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)							
SEATTL	E W	VA.	98104										X	Form file	d by One	Report	ing Person	
-														Form file	d by More	than (	One Reporti	ng Person
(City)	(S	State)	(Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/L			ite	2A. Deemed Execution Date, if any (Month/Day/Yea		, Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and 5)			5. Amount Securities Beneficiall Owned Fol	Form: (D) or		: Direct In r Indirect B str. 4) O	. Nature of ndirect leneficial ownership			
								Code	v	Amount	unt (A) or Pr		Price	Reported Transactio (Instr. 3 an	ion(s)		(	nstr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, Curity or Exercise (Month/Day/Year) if any Code		Transa Code	saction Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		rlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title		unt or ber of es	t or (Instr. 4)				
Stock Option (right to buy)	\$1.25	02/24/2022		A		1,900,000		(1)	02	2/24/2032	Common Stock	1,90	00,000	\$0	1,900,0	000	D	

## **Explanation of Responses:**

1. The options will vest on a quarterly basis over two (2) years.

/s/ Steven Quay 02/28/2022

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.